Nicotinic acetylcholine receptors in separate brain regions exhibit different affinities for methyllycaconitine.
The family of nicotinic acetylcholine receptors contains numerous subtypes. Since the subunit compositions of most native neuronal nicotinic receptors are unknown, an important method for distinguishing subtypes of functional neuronal receptors is based on pharmacological criteria, such as affinity for snake toxins. We have now examined the affinities of native chick nicotinic receptors for methyllycaconitine, a toxin purified from Delphinium. We find that methyllycaconitine is a potent antagonist at central nicotinic receptors located on Edinger-Westphal neurons, producing nearly complete functional blockade of nicotinic responses at 10 nM. In marked contrast, methyllycaconitine is 1000-fold less potent at blocking nicotinic responses in the lateral spiriform nucleus. Methyllycaconitine inhibits kappa-bungarotoxin-sensitive nicotinic receptors in ciliary ganglia at 0.5-1.0 microM. Radioligand binding studies also reveal heterogeneity in the affinity of the toxin for nicotinic receptors. Methyllycaconitine binds most avidly to [125I] alpha-bungarotoxin sites in brain (Ki = 5.4 nM), and is 200-fold less potent at muscle nicotinic receptors (IC50 = 1.1 microM). The least potent binding of the toxin is to [3H]nicotine sites in brain (Ki = 3.7 microM). Methyllycaconitine is thus a useful pharmacological tool for distinguishing certain subtypes of native nicotinic receptors. The relatively low affinity of the toxin for nicotinic receptors in the lateral spiriform nucleus is consistent with the known properties of these receptors, which include a high affinity for [3H]nicotine and a lack of sensitivity to alpha- and kappa-bungarotoxin. On the basis of high affinity for methyllycaconitine and insensitivity to alpha-bungarotoxin, the nicotinic receptors in the Edinger-Westphal nucleus are unlike any previously described nicotinic receptor subtype.
Yum
L
L
Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, MO 63104, USA.
Wolf
K M
KM
Chiappinelli
V A
VA
D000157:Aconitine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000818:Animals; D001921:Brain / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism*; D002038:Bungarotoxins / Q000494:pharmacology; D002217:Carbachol / Q000378:metabolism; D002642:Chick Embryo; D005110:Extracellular Space / Q000378:metabolism; D005726:Ganglia, Parasympathetic / Q000378:metabolism; D066298:In Vitro Techniques; D007457:Iodine Radioisotopes; D018482:Muscle, Skeletal / Q000378:metabolism; D009538:Nicotine / Q000378:metabolism; D011869:Radioligand Assay; D051381:Rats; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000378:metabolism*
D002038:Bungarotoxins; D007457:Iodine Radioisotopes; D011978:Receptors, Nicotinic; C054634:methyllycaconitine; D009538:Nicotine; D002217:Carbachol; D000157:Aconitine